Objective: To determine whether depressive symptoms are associated with medial temporal lobe atrophy in older people with and without Alzheimer disease (AD). Method: A total of 368 memory clinic patients with AD, mild cognitive impairment, and subjective cognitive impairment (SCI) were included. Depressive symptoms were defined as a score of 8 or higher on Cornell Scale for Depression in Dementia or use of antidepressant medications. Magnetic resonance imaging and computer tomography scans were rated for medial temporal lobe atrophy (MTA), using the Scheltens scale. For a subsample (n ¼ 57 patients), hippocampal volume was manually traced. Results: Based on visual assessment, AD patients with depressive symptoms had less atrophy of the right medial temporal lobe (odds ratio [OR] for having MTA: 0.39; 95% confidence interval [CI] 0.16-0.99) and decreased scores on Scheltens scale for the left medial temporal lobe (OR: 0.43, 95% CI 0.19-0.96) in comparison to AD patients without depressive symptoms. In the subgroup where manual tracing was used to measure hippocampal volume, people with SCI experiencing depressive symptoms had smaller right (mean difference: 0.28 cm 3 ; P ¼ .005) and left (mean difference 0.32 cm 3 ; P ¼ .002) hippocampal volumes compared to people with SCI who did not have depressive symptoms. Conclusion: Hippocampal atrophy was more pronounced among patients having SCI with depressive symptoms, while the medial temporal lobe was less atrophic in patients having AD with depressive symptoms than those without depressive symptoms. These findings suggest that different mechanisms underlie depression in older people with and without AD and may explain some of the inconsistent observations in previous studies.
Introduction
Depression and cognitive impairment are among the most common conditions in older people and are frequently concurrent. 1 The prevalence of depression in patients with mild cognitive impairment (MCI) and with Alzheimer disease (AD) is high (frequencies ranging from 3%-83% in MCI and 20%-30% in patients with AD, depending on studies design and methods) 2, 3 and is associated with more severe cognitive impairment, poor response to antidepressant therapy, and higher morbidity. 1 The relationship between depression and dementia is complex and not completely understood: early-onset depression has been reported to be a risk factor for dementia, 4 whereas lateonset depression can be an early symptom of dementia. 5 In addition, some pathologies such as microvascular disease are common in people with AD but are also an important risk factor for depression. 6 Structural and functional changes in the brain and hippocampus in particular have been reported in animal and human studies to play a key role in memory and in depression. 7 It is known that hippocampus is very sensitive to the increased cortisol levels and decreased levels of serotonin and growth factors (eg, brain-derived neurotophic factor; BDNF) found in depression 8, 9 and also in AD as a consequence of early amyloid-b (Ab) accumulation. 10 This leads to the hypotheses that depression increases the risk of AD and that AD pathology may also contribute to increased risk of depression via hippocampal atrophy. There is also a suggestion from postmortem studies that depression in people with AD may be associated with specific patterns of atrophy involving the locus coeruleus and substantia nigra, with relative preservation of the temporal cortex 11 and with an increase in AD pathology. 12, 13 Furthermore, the conclusions of the studies about hippocampal volume and depression in older people without dementia are inconsistent. Several magnetic resonance imaging (MRI) and postmortem studies [14] [15] [16] suggest an association between decreased hippocampal volume and depression, whereas others did not report a significant association. 17, 18 It is also controversial whether depression is the cause of hippocampal atrophy in older people or whether reduced hippocampal volume induced by genetic or other factors leads to depression and subsequently to AD. 19 In summary, although few studies exist, there is emerging evidence that depression in late life and AD share similar underlying mechanisms, such as inflammation, neurogenesis, and neurotransmitters disturbance, 9 with hippocampus playing a central role as a common intermediate. The present article tests the hypothesis that depressive symptoms are associated with medial temporal lobe atrophy in older patients with a broad range of cognitive performance. The inclusion criteria for the current project are as follows: (1) patients aged 55 or older, (2) completed Cornell Scale for Depression in Dementia (CSDD), (3) MRI or computer tomography (CT) available, and (4) diagnosis of AD, MCI, or SCI with normal cognition on neuropsychological testing. Excluded were patients with (1) traumatic brain injuries and history of severe psychiatric disorders or somatic diseases significantly affecting cognitive performance, (2) life-threatening disease with expected reduced survival time including cancer, and (3) dementia disorders others than AD. In total, 843 of 1211 patients did not fulfill the inclusion and exclusion criteria.
Methods

Recruitment of Participants
The study was approved by the Ethical Committee at Karolinska University Hospital in Huddinge (43/03) and by the Regional Ethical Review Board in Stockholm (DNR: 2010/ 1817-31/2, 2011/1987 31/4). All patients provided written consent to use clinical information for research.
Diagnostic Procedures
Participants underwent a standard protocol that included patient and informant interview performed by a physician; information of previous depression and current use of antidepressants was obtained. A clinical examination included neurological status, measurement of functional status with Informant Questionnaire on Cognitive Decline in the Elderly, 20,21 cognitive screening with Mini-Mental State examination (MMSE) and Clock Drawing Test, detailed neuropsychological examination in most cases, brain imaging techniques (MRI or CT scans), routine blood chemistry and cerebrospinal fluid (CSF) analyses including conventional biomarkers of neurodegeneration Ab 1-42, total tau (t-tau), and phosphorylated tau 181 (p-tau).
Diagnoses of AD, MCI, and SCI were made after a consensus meeting with licensed specialists in neurology, geriatric medicine and psychiatry, nurses, neuropsychologists, and speech therapist taking into account all available information.
Diagnosis
Patients were Diagnosed as AD According to International Classification of Diseases, Tenth Revision Criteria
The diagnosis of MCI was made according to revised clinical criteria of Winblad et al, 22 which require subjective cognitive complaints, impairment on objective cognitive tests, normal global cognitive function, no significant impairment of activities of daily living and no dementia.
The diagnosis of SCI was made if the examination and neuropsychological tests did not show evidence of cognitive impairment, that is, neither dementia nor MCI criteria were fulfilled, although the patients and/or their close informant reported changes in the patients' cognitive status compared to the premorbid level.
Depressive Symptoms
Depressive symptoms were assessed using a combined patient and informant-based scale, CSDD, which has good psychometric properties in both individuals with and without dementia. 23, 24 This is a 19-item scale and scores range between 0 and 38. Each item can be scored between 0 (not present), 1 (mild or intermittent), 2 (often present), and a (unable to evaluate the item). The CSDD was completed by a licensed geriatrician or psychiatrist or a trained geriatric nurse specialist. In the original scale, the 19 items are grouped into mood-related signs, behavioral disturbance, physical signs, cyclic function, and ideational disturbance. We present the subscale scores in Table 1 .
We defined depressive symptoms as 8 or more points on CSDD as suggested by the original author of the scale 23 or use of antidepressants since this has been reported to increase classification accuracy. 4 In a recent study with memory clinic outpatients, it has been shown that CSDD score !8 has an adequate sensitivity and specificity to diagnose depression in elderly patients without dementia (53% and 91%, respectively) and with dementia (75% and 69%, respectively). 25 
Image Acquisition
Magnetic resonance imaging was performed using 1.5T Siemens Vision (Symfoni and Avanto) scanner (Siemens, Erlangen, Germany). The T1-weighted 3D MPRAGE sequence was acquired using the following parameters: repetition time, 11.4 ms; echo time, 4.4 ms; flip angle, 10 ; number of slices, 72 continuous coronal slices; and slice thickness, 2.5 mm. A good separation between gray and white matter was obtained.
Visual Assessment of the Medial Temporal Lobe
Since good agreement between multidetector row CT and 1.5T MRI had been shown for visual assessment of the medial temporal lobe (vaMTL), 26 we included both MRI (n ¼ 295, 80.16%) and CT (n ¼ 73, 19 .84%) scans. The neuroradiologic investigations were performed in different radiology departments, in hospitals, or in private radiology clinics in Stockholm and neighboring counties, with different MRI and CT equipment and different protocols.
Magnetic resonance imagingand CT images were oriented to oblique coronal sections suitable for visual assessment. Medial temporal lobe was rated using Scheltens scale, 27 which is based on a visual estimation of volume of the medial temporal lobe. The visual assessment includes hippocampus proper, dentate gyrus, subiculum, parahippocampal gyrus, entorhinal cortex, and surrounding CSF spaces such as the temporal horns and choroid fissure. This is a 5-point scale that ranges from 0 (no atrophy) to 4 (end stage), and it is applied to the right and left medial temporal lobes separately. Since medial temporal lobe volume is age dependent, we considered as normal vaMTL scores 0 to 1 in persons less than 70 years, vaMTL 2 between 70 and 80 years, and vaMTL 3 older than 80 years according to the findings from a recent study. 28 Medial temporal lobe atrophy was defined as vaMTL scores above the age reference values ( Figure 1 ).
Manual Tracing
In addition, manual measurement of the hippocampal volumes was performed on MRI scans of 57 patients, following the protocol proposed by Malykhin et al. 29 The hippocampus exhibits relatively small anatomical variability compared with cortical regions, and high reliability in manual tracing has been reported. The total intracranial volume (TICV) was obtained using a stereologic point-counting technique, consisting of normal tracing of the ICV on every forth section, following the landmarks proposed by Eritaia et al's 30 image with the manual tracing technique. Right and left hippocampal volumes (in cm 3 ) were separately delineated and normalized by TICV using the method of Jack et al 31 : volume (adjusted) ¼ volume (observed) À b (slope of the regression line of hippocampal volume regressed on TICV) Â (TICV the subject TICV À TICV sample mean).
Intrarater Reliability
Both vaMTL and hippocampal manual tracing were performed by experienced raters (LC and BBZ) 32 who were blinded to CSDD scores, antidepressant therapy and clinical diagnosis. Intrarater reliability was assessed using intraclass correlation coefficients (ICCs). For vaMTL, ICC was 0.81 on right side and 0.78 on left side, data published elsewhere, 33 whereas for manual hippocampus outline, ICC was 0.91. 32 Mood-related signs, median (range)
Abbreviations: SCI, subjective cognitive impairment; MCI, mild cognitive impairment; AD, Alzheimer disease. a Mood-related signs includes anxiety, sadness, lack of reactivity to pleasant events, irritability; behavioral disturbance includes agitation, retardation, multiple physical complains, loss of interest; Physical signs includes appetite loss, weight loss, lack of energy; Cyclic functions includes diurnal variation of mood, difficulty falling asleep, multiple awakenings during sleep, early morning awakenings; ideational disturbance includes suicide, poor self-esteem, pessimism, mood congruent delusions.
Statistics
Statistical analyses were performed in SPSS Version 20.0 Comparisons between patients with and without depressive symptoms were made using parametric (Student t tests) or nonparametric tests (chi-square tests, Mann-Whitney, and Kruskal Wallis test) as appropriate in AD, MCI and SCI groups.
To address the association between MTA and depressive symptoms, regression models were built using unconditional logistic (MTA yes/no) or ordered logistic regression (taking into account the full scale) adjusting for potential confounders. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated, and all models were adjusted for gender, years of education and MMSE.
For the analyses based on manual tracing, the normal distribution of the hippocampal volumes was ascertained using Kolmogorov-Smirnov test. Generalized linear model was used to estimate mean and mean differences between hippocampal volumes in patients with and without depressive symptoms. Linear regression was used to estimate b coefficients and p value between hippocampal volume and Cornell scale for depression in dementia. All models were adjusted for age, gender, MMSE scores, and years of education. In additional analyses, depressive symptoms were defined as CSDD scores !8 and use of antidepressant treatment as separate variable; CSDD scores were used as continuous variable for the subsample of 57 patients.
Results
Association Between Depressive Symptoms and visual assessment of the medial temporal lobe
Of the 368 patients (Table 2) , 119 (32.3%) had a CSDD score above the cutoff !8 and 116 (31.5%) were using antidepressants. According to the study definition, 182 (49.5%) had depressive symptoms. As seen in Table 2 , patients having SCI, MCI, and AD with and without depressive symptoms did not differ with regard to age, MMSE scores, or years of education, but depressive symptoms were more frequent among females with MCI. As expected, vaMTL scores increased significantly from SCI to MCI to AD (right vaMTL H(2) ¼ 44.42, p < .0001 and left vaMTL H(2) ¼ 48.57, p < .0001; data not shown).
As shown in Table 3 , in patients with AD, for each increase with 1 point on left vaMTL scale, the odds for having more depressive symptoms decrease with 57% (adjusted regression: OR 0.43; 95% CI 0.19-0.96). Right MTA was associated with a decreased OR of depressive symptoms (adjusted regression: OR 0.39; 95% CI 0.16-0.99). We also performed this analysis requiring at least 1 mood-specific item and obtained a similar pattern. Patients with AD and depressive symptoms had a near-significant decreased OR for having right MTA (OR: 0.39, 95% CI: 0.14-1.04).
Using the recommended age cutoff of 75 of Scheltens et al 27 , we observed a similar pattern. In the AD group, depressive symptoms were associated with decreased likelihood of right MTA (OR: 0.45; 95% CI: 0.18-1.11; if depressive symptoms are 
Hippocampal Volume-Manual Measurement
The characteristics of the 57 patients where manual volumetric measurements were performed are presented in Table 4 . Of these, 19.3% (n ¼ 11) had a CSDD score above the cutoff !8 and 47.4% (n ¼ 27) use antidepressants; according to our definition, 57.9% (n ¼ 33) had depressive symptoms. Those with and without depressive symptoms did not differ significantly with regard to age, gender, MMSE scores or years of education.
As expected, patients with SCI had a significantly larger hippocampal volume on both sides compared to patients with AD (right: p ¼ .0001 and left: p ¼ .015; data not shown).
In the SCI group, patients with depressive symptoms have smaller hippocampal volumes (mean value for right is 2.60 cm 3 and left 2.45 cm 3 ) compared to patients without depressive symptoms (mean values for right is 2.88 cm 3 and left 2.77 cm 3 ). In the adjusted analyses, mean difference and p value for the left hippocampal volume were À0. 32, p ¼ .002, and for the right hippocampal volume were À0.28, p ¼ .005 (Table 5 ). In the AD group, depressive symptoms were not associated with right or left hippocampal volumes.
We repeated all analyses with CSDD scores and antidepressant therapy as separate independent variables. In the SCI group, we found an association between right hippocampal volume and antidepressant therapy (mean difference ¼ À0. 22 and p ¼ 0.03) and between CSDD total score and left hippocampal volume (b coefficient ¼ 0.04 and p ¼ .01; Table 5 ).
Discussions
In this study, we tested the hypothesis that depressive symptoms are associated with atrophy of medial temporal lobe structures in older people with different degrees of cognitive impairment. Our findings provide support for the hypothesis in participants with SCI. However, this pattern was not seen in patients with AD nor with MCI. In fact, in the analyses of the full sample, patients with AD and depressive symptoms had relative preservation of the medial temporal lobe compared to those without depressive symptoms. These findings suggest that different mechanisms are underlying depression in older people with and without AD.
Using manual tracing, a more atrophic hippocampus was present in patients with SCI having depressive symptoms, consistent with many previous studies both in older and in younger adults. 14 The mechanism for this association is still, however, unclear. Since patients with SCI are at risk to develop AD, one possibility is that the atrophy seen in some SCI reflects early AD changes. 34 This hypothesis is supported by Steffens et al 15 who reported smaller left hippocampi as a risk factor for cognitive decline in patients with late-life depression. In contrast, another study reports a greater degree of hippocampal atrophy in patients having SCI without depressive symptoms than those with depressive symptoms. 35 A further possible explanation is that the atrophy is induced by depressionassociated changes such as decreased level of BDNF and serotonin and increased level of cortisone. 6 The lack of such an association or even an opposite association between medial temporal lobe and depressive symptoms was found in AD. Contrary to our hypothesis, those with depressive symptoms have less atrophic medial temporal lobe, despite having similar level of cognitive impairment. One possible explanation is that in the presence of depressive symptoms, less AD type changes are needed to reach the same degree of cognitive impairment as seen in patients having AD without depressive symptoms since depressive symptoms are in itself associated with lower cognitive performance. This association between depression and cognitive impairment has been shown in many studies. 36, 37 This hypothesis supports the idea that depressive symptoms occur in early stages of dementia and is consistent with our previous findings 38 that patients having AD with depressive symptoms have lower levels of CSF markers of neurodegeneration (ie, t-tau). The findings are also consistent with previous neuropathological studies suggesting a specific pattern of atrophy in patients with AD having depression, involving relative sparing of the temporal cortex. 11 In addition, a recent clinicopathological study did not suggest that AD pathology was associated with depression. 39 Thus, the differential associations between depression and hippocampal volume depending on AD diagnosis may at least partly explain the previous inconsistent findings in studies exploring this association in the elderly patients. Our findings suggest that the association between depression and hippocampus is dependent on whether patients with AD are included or not included.
Methodological limitations of the current study include the cross-sectional design, and thus assumptions regarding causality cannot be made. The study sample was selected from referrals to a university memory clinic, and thus generalizations to the population are not possible. In particular, the non-AD group was selected from people with SCI, with an increased proportion of MTA, and thus extrapolation to nondemented old people with depressive symptoms in general cannot be made.
Another limitation is that depression was classified based on a severity scale scores and not on a diagnosis. Although nurses and clinicians were trained to use the CSDD, we do not have data on the level of reliability among users. There is yet no established consensus as to the optimal way to define clinically relevant depression and depressive symptoms in AD. The depressive symptoms were of mild to moderate severity, and different findings may emerge if patients with more severe depression were included.
Clinical features such as history of depression (age at onset, number, and length of episodes) might have influenced the findings but were not available. Mechanisms underlying early-and late-onset depression may differ, 14, 40 but due to insufficient data, we could not perform stratified analyses for depression onset. Similarly, we had no information of the duration and indication of previous antidepressant therapy.
Diagnosis of AD was clinical, and thus there is a possibility of misdiagnosis. However, in addition to employing a comprehensive and standardized battery of clinical scales, we also used the neuropsychological tests as well as CSF AD biomarkers to aid in the diagnosis.
Moreover, the differences between the 2 methods used to evaluate the MRI scans can explain the different results in patients with SCI and AD. The vaMTL includes hippocampus and other anatomical structures like entorhinal cortex which has been associated with late-onset depression 40 and early AD pathology. 41 This method is commonly used in clinical practice, but the method is less accurate for detecting subtle variations. However, in a subset of participants manual delineation of the hippocampus was performed which is considered the gold standard method for evaluating hippocampal volume, although it is time consuming and not applicable for clinical purposes or in large cohorts. 32 A possible methodological limitation is that the results were not corrected for multiple statistical comparisons; however, the performed analyses lead to robust results.
Finally, brain changes that were not assessed might have influenced the findings. For example, late-onset depression has been associated with increased vascular pathology represented by white matter lesions 6 and in volumetric changes in regions other than hippocampus.
In conclusion, we identified significant associations between depressive symptoms and medial temporal lobe structures, which varied according to cognitive diagnosis, whereas depressive symptoms were associated with hippocampal atrophy in people with normal cognition at cognitive testing, such an association was not evident in people with AD. This may suggest different mechanisms underlying depression in people with and without AD, which is consistent with recent reports that antidepressants are not effective in patients having AD with depression. 42 Further research is needed, using a longitudinal design, to explore the mechanisms leading to depression in people with AD and the relationship between depressive symptoms and AD-related pathologies and to develop more specific and more effective therapies.
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